Cargando…
Comprehensive Evaluation of Multiple Approaches Targeting ABCB1 to Resensitize Docetaxel-Resistant Prostate Cancer Cell Lines
Docetaxel (DTX) is a mainstay in the treatment of metastatic prostate cancer. Failure of DTX therapy is often associated with multidrug resistance caused by overexpression of efflux membrane transporters of the ABC family such as the glycoprotein ABCB1. This study investigated multiple approaches ta...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820728/ https://www.ncbi.nlm.nih.gov/pubmed/36614114 http://dx.doi.org/10.3390/ijms24010666 |
_version_ | 1784865531556265984 |
---|---|
author | Linke, Dinah Donix, Lukas Peitzsch, Claudia Erb, Holger H. H. Dubrovska, Anna Pfeifer, Manuel Thomas, Christian Fuessel, Susanne Erdmann, Kati |
author_facet | Linke, Dinah Donix, Lukas Peitzsch, Claudia Erb, Holger H. H. Dubrovska, Anna Pfeifer, Manuel Thomas, Christian Fuessel, Susanne Erdmann, Kati |
author_sort | Linke, Dinah |
collection | PubMed |
description | Docetaxel (DTX) is a mainstay in the treatment of metastatic prostate cancer. Failure of DTX therapy is often associated with multidrug resistance caused by overexpression of efflux membrane transporters of the ABC family such as the glycoprotein ABCB1. This study investigated multiple approaches targeting ABCB1 to resensitize DTX-resistant (DTXR) prostate cancer cell lines. In DU145 DTXR and PC-3 DTXR cells as well as age-matched parental controls, the expression of selected ABC transporters was analyzed by quantitative PCR, Western blot, flow cytometry and immunofluorescence. ABCB1 effluxing activity was studied using the fluorescent ABCB1 substrate rhodamine 123. The influence of ABCB1 inhibitors (elacridar, tariquidar), ABCB1-specific siRNA and inhibition of post-translational glycosylation on DTX tolerance was assessed by cell viability and colony formation assays. In DTXR cells, only ABCB1 was highly upregulated, which was accompanied by a strong effluxing activity and additional post-translational glycosylation of ABCB1. Pharmacological inhibition and siRNA-mediated knockdown of ABCB1 completely resensitized DTXR cells to DTX. Inhibition of glycosylation with tunicamycin affected DTX resistance partially in DU145 DTXR cells, which was accompanied by a slight intracellular accumulation and decreased effluxing activity of ABCB1. In conclusion, DTX resistance can be reversed by various strategies with small molecule inhibitors representing the most promising and feasible approach. |
format | Online Article Text |
id | pubmed-9820728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98207282023-01-07 Comprehensive Evaluation of Multiple Approaches Targeting ABCB1 to Resensitize Docetaxel-Resistant Prostate Cancer Cell Lines Linke, Dinah Donix, Lukas Peitzsch, Claudia Erb, Holger H. H. Dubrovska, Anna Pfeifer, Manuel Thomas, Christian Fuessel, Susanne Erdmann, Kati Int J Mol Sci Article Docetaxel (DTX) is a mainstay in the treatment of metastatic prostate cancer. Failure of DTX therapy is often associated with multidrug resistance caused by overexpression of efflux membrane transporters of the ABC family such as the glycoprotein ABCB1. This study investigated multiple approaches targeting ABCB1 to resensitize DTX-resistant (DTXR) prostate cancer cell lines. In DU145 DTXR and PC-3 DTXR cells as well as age-matched parental controls, the expression of selected ABC transporters was analyzed by quantitative PCR, Western blot, flow cytometry and immunofluorescence. ABCB1 effluxing activity was studied using the fluorescent ABCB1 substrate rhodamine 123. The influence of ABCB1 inhibitors (elacridar, tariquidar), ABCB1-specific siRNA and inhibition of post-translational glycosylation on DTX tolerance was assessed by cell viability and colony formation assays. In DTXR cells, only ABCB1 was highly upregulated, which was accompanied by a strong effluxing activity and additional post-translational glycosylation of ABCB1. Pharmacological inhibition and siRNA-mediated knockdown of ABCB1 completely resensitized DTXR cells to DTX. Inhibition of glycosylation with tunicamycin affected DTX resistance partially in DU145 DTXR cells, which was accompanied by a slight intracellular accumulation and decreased effluxing activity of ABCB1. In conclusion, DTX resistance can be reversed by various strategies with small molecule inhibitors representing the most promising and feasible approach. MDPI 2022-12-30 /pmc/articles/PMC9820728/ /pubmed/36614114 http://dx.doi.org/10.3390/ijms24010666 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Linke, Dinah Donix, Lukas Peitzsch, Claudia Erb, Holger H. H. Dubrovska, Anna Pfeifer, Manuel Thomas, Christian Fuessel, Susanne Erdmann, Kati Comprehensive Evaluation of Multiple Approaches Targeting ABCB1 to Resensitize Docetaxel-Resistant Prostate Cancer Cell Lines |
title | Comprehensive Evaluation of Multiple Approaches Targeting ABCB1 to Resensitize Docetaxel-Resistant Prostate Cancer Cell Lines |
title_full | Comprehensive Evaluation of Multiple Approaches Targeting ABCB1 to Resensitize Docetaxel-Resistant Prostate Cancer Cell Lines |
title_fullStr | Comprehensive Evaluation of Multiple Approaches Targeting ABCB1 to Resensitize Docetaxel-Resistant Prostate Cancer Cell Lines |
title_full_unstemmed | Comprehensive Evaluation of Multiple Approaches Targeting ABCB1 to Resensitize Docetaxel-Resistant Prostate Cancer Cell Lines |
title_short | Comprehensive Evaluation of Multiple Approaches Targeting ABCB1 to Resensitize Docetaxel-Resistant Prostate Cancer Cell Lines |
title_sort | comprehensive evaluation of multiple approaches targeting abcb1 to resensitize docetaxel-resistant prostate cancer cell lines |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820728/ https://www.ncbi.nlm.nih.gov/pubmed/36614114 http://dx.doi.org/10.3390/ijms24010666 |
work_keys_str_mv | AT linkedinah comprehensiveevaluationofmultipleapproachestargetingabcb1toresensitizedocetaxelresistantprostatecancercelllines AT donixlukas comprehensiveevaluationofmultipleapproachestargetingabcb1toresensitizedocetaxelresistantprostatecancercelllines AT peitzschclaudia comprehensiveevaluationofmultipleapproachestargetingabcb1toresensitizedocetaxelresistantprostatecancercelllines AT erbholgerhh comprehensiveevaluationofmultipleapproachestargetingabcb1toresensitizedocetaxelresistantprostatecancercelllines AT dubrovskaanna comprehensiveevaluationofmultipleapproachestargetingabcb1toresensitizedocetaxelresistantprostatecancercelllines AT pfeifermanuel comprehensiveevaluationofmultipleapproachestargetingabcb1toresensitizedocetaxelresistantprostatecancercelllines AT thomaschristian comprehensiveevaluationofmultipleapproachestargetingabcb1toresensitizedocetaxelresistantprostatecancercelllines AT fuesselsusanne comprehensiveevaluationofmultipleapproachestargetingabcb1toresensitizedocetaxelresistantprostatecancercelllines AT erdmannkati comprehensiveevaluationofmultipleapproachestargetingabcb1toresensitizedocetaxelresistantprostatecancercelllines |